The ECJ confirms Commission must assess whether an agreement to limit parallel trade in medicines has pro-competitive benefits (GlaxoSmithKline)

On 6 October, the European Court of Justice (‘ECJ’) issued another “score draw” judgment [1] in the long-running battle of R&D-based pharmaceutical companies to limit parallel trade in medicines across the EU. While the ECJ required the European Commission to conduct an in-depth examination of whether EU competition rules can be declared inapplicable to GlaxoSmithKline’s Spanish general sales conditions, it also confirmed that an agreement limiting parallel trade is a restriction of competition “by object”. Provided pharmaceutical companies can put forward cogent evidence of appreciable efficiencies, the need to conduct a full investigation into whether an exemption is available is unlikely

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Anne Wachsmann, Sir Christopher Bellamy, Olivier D'Ormesson, Robert Gavin, Jeffrey Schmidt, Gerwin Van Gerven, The ECJ confirms Commission must assess whether an agreement to limit parallel trade in medicines has pro-competitive benefits (GlaxoSmithKline), 6 octobre 2009, Bulletin e-Competitions October 2009, Art. N° 41281

Visites 930

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues